CAR T-Cell Therapy: Changing the Treatment Landscape for Hematologic Malignancies

Join us for this dynamic CME-certified symposium, in which an expert panel will discuss current best practices and emerging strategies in using CAR T-cell therapies for patients with lymphomas, leukemias, and myeloma. Sign up now!

To Register:

Please note: You must be registered to attend the 2021 Transplantation & Cellular Therapy MeetingsSM of ASTCT® and CIBMTR® to attend this symposium.


CAR T-Cell Therapy in Lymphomas

CAR T-Cell Therapy for Myeloma

CAR T-Cell Therapies for R/R ALL

Best Practices in Identifying and Managing CAR T-Cell–Mediated Toxicities


Date / Time
Event Details


Program Director
Renier J. Brentjens, MD, PhD

Associate Professor
Department of Medicine
Weill Medical College of Cornell University
Associate Professor
Department of Pharmacology
Weill Cornell Graduate School of Medical Sciences
Associate Attending
Department of Medicine
Memorial Sloan Kettering Cancer Center
New York, New York

Frederick L. Locke, MD

Co-Leader, Moffitt Immuno-Oncology Program
Vice Chair and Associate Member
Department of Blood and Marrow Transplant and Cellular Immunotherapy
Research Director
Medical Director

Immune Cell Therapy Program
Blood and Marrow Transplant and Cellular Immunotherapy
Moffitt Cancer Center
Tampa, Florida

Noopur Raje, MD

Director, Center for Multiple Myeloma
Massachusetts General Hospital Cancer Center
Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Goal Statement
The goal of this activity is to improve the knowledge, competence, and performance of physicians and other healthcare providers so they can confidently and competently integrate CAR T-cell therapy into their clinical practices.

Target Audience 
This program is intended for physicians and other healthcare providers who treat and manage patients with B-cell lymphomas, CLL, or multiple myeloma who are candidates for CAR T-cell therapies.

Learning Objectives 

  • Review the biologic principles underlying CAR T-cell therapy, structure and function of the CAR, and the mechanism of action of CAR T-cells
  • Identify characteristics of patients who are candidates appropriate for treatment with CAR T-cell therapy
  • Integrate into practice clinical trial data on CAR T-cell–based therapies for the treatment of patients with leukemia or B-cell lymphomas
  • Evaluate emerging clinical data and novel approaches to CAR T-cell therapy for patients with myeloma or CLL
  • Manage toxicities associated with CAR T-cell therapy using available guidelines and online clinical resources and tools


Continuing Medical and Professional Education

2021 TCT | Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR are sponsored by the Medical College of Wisconsin.

ACCME Accreditation Statement
The Medical College of Wisconsin is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education to physicians.

AMA Credit Designation
The Medical College of Wisconsin designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Hours of Participation for Allied Health Professionals
The Medical College of Wisconsin designates this activity for up to 1.00 hours participation for continuing education for allied health professionals.